by Prateek Chopra | June 1, 2026 | Cardiology Conferences | ESH 2026
Clinical Background:
Accurate cardiovascular risk assessment is central to hypertension management and prevention strategies. Contemporary approaches emphasize integrated cardiovascular-kidney-metabolic (CKM) risk evaluation to improve early detection, individualized therapy, and long-term cardiovascular outcomes.
Evidence & Risk Tools:
- Major cardiovascular risk prediction models: WHO CVD risk charts, Globorisk, INTERHEART, SCORE2, SCORE2-OP.
- Differences in derivation cohorts, regional applicability, risk variables, and implementation approaches highlight the need for population-specific risk assessment.
- WHO CVD risk charts emphasized for regional adaptability and practical use in low-resource settings.
Implementation Strategies:
- HEARTS initiative and HEARTS 2.0 clinical pathway for hypertension and CKM prevention.
- Key components: standardized BP measurement, simplified pharmacological protocols, validated BP devices, early CKM screening, continuity of care in primary healthcare systems.
- HEARTS in the Americas: largest WHO implementation; 33 participating countries, ~10,000 primary healthcare facilities, standardized clinical pathways across 28 countries.
Clinical Implications:
- Integrating cardiovascular risk tools with structured hypertension management strengthens early detection, improves treatment standardization, and supports long-term prevention.
- Effective implementation requires validated clinical tools, simplified treatment algorithms, and robust primary healthcare systems.
Structured integration of CKM risk assessment, validated risk prediction tools, and standardized hypertension management pathways improves global cardiovascular prevention and blood pressure control.